Seres Therapeutics Inc
MCRB14.140USD
+0.150+1.07%
交易中 （美东）报价延迟15分钟
6.17M总市值
0.08市盈率 TTM
关于 Seres Therapeutics Inc 公司
Seres Therapeutics, Inc. 是一家临床阶段公司，专注于通过新型活体生物疗法改善医学上脆弱人群的患者治疗效果。该公司致力于开发 SER-155，在接受异基因造血干细胞移植 (allo-HSCT) 的患者的临床研究中，该药物已证明显著减少血液感染和相关并发症（与安慰剂相比）。该公司还在推进针对医学上脆弱人群的其他培养口服活体生物疗法，包括患有慢性肝病、癌症中性粒细胞减少症和实体器官移植的患者。该公司在其各个项目中的临床和非临床数据支持开发活体生物疗法，以预防和治疗广泛的感染以及炎症和免疫疾病。
公司简介
公司代码MCRB
公司名称Seres Therapeutics Inc
上市日期Jun 26, 2015
CEOMr. Thomas J. DesRosier, J.D.
员工数量103
证券类型Ordinary Share
年结日Jun 26
公司地址101 Cambridge Park Drive
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02140
电话16179459626
网址https://www.serestherapeutics.com/
公司代码MCRB
上市日期Jun 26, 2015
CEOMr. Thomas J. DesRosier, J.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
--
--
Dr. Claire M. Fraser, Ph.D.
Dr. Claire M. Fraser, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Co-President, Co-Chief Executive Officer, Chief Financial Officer
Co-President, Co-Chief Executive Officer, Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明细
FY2023
FY2022
FY2021
暂无数据
地区USD
名称
营收
占比
United States
126.33M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
持股股东
持股股东
占比
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
股东类型
持股股东
占比
Investment Advisor
19.23%
Venture Capital
13.24%
Corporation
12.47%
Investment Advisor/Hedge Fund
1.46%
Research Firm
1.04%
Individual Investor
0.59%
Hedge Fund
0.45%
Bank and Trust
0.05%
Other
51.47%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
284
4.24M
48.53%
-1.00M
2025Q1
303
4.22M
48.29%
-1.11M
2024Q4
311
85.93M
50.33%
-20.68M
2024Q3
330
86.09M
50.57%
-26.54M
2024Q2
336
69.70M
45.95%
-51.91M
2024Q1
345
94.53M
65.81%
-35.72M
2023Q4
345
98.23M
75.49%
-30.72M
2023Q3
356
117.05M
93.47%
-19.47M
2023Q2
384
121.97M
97.71%
-18.66M
2023Q1
378
115.00M
93.33%
-29.90M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Flagship Ventures
1.16M
13.24%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.09M
12.51%
+2.16K
+0.20%
Mar 31, 2025
Nestle SA
1.09M
12.47%
+709.39K
+186.83%
Sep 30, 2024
The Vanguard Group, Inc.
304.60K
3.49%
+10.91K
+3.71%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
84.10K
0.96%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
80.94K
0.93%
+5.42K
+7.17%
Mar 31, 2025
Bank Vontobel AG
54.30K
0.62%
+7.38K
+15.74%
Mar 31, 2025
UBS Financial Services, Inc.
69.22K
0.79%
+52.11K
+304.43%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
41.70K
0.48%
-1.59K
-3.66%
Mar 31, 2025
Susquehanna International Group, LLP
35.86K
0.41%
+19.47K
+118.77%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
iShares Russell 2000 Growth ETF
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
Proshares Ultra Russell 2000
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
Invesco RAFI US 1500 Small-Mid ETF
占比0%
Direxion Daily S&P Biotech Bull 3X Shares
占比0%
iShares Russell 2000 Growth ETF
占比0%
iShares Biotechnology ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 ETF
占比0%
FlexShares Morningstar US Market Factor Tilt Index Fund
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
